Consolidated statements of income In millions of US dollars, except share and per share data 2012 2011 2010 Notes $M $M $M Revenues Product sales 4,406.7 3,950.2 3,128.2 Royalties 241.6 283.5 328.1 Other revenues 32.9 29.7 14.8 Total revenues 4,681.2 4,263.4 3,471.1 Costs and expenses 1 Cost of product sales 645.4 588.1 463.4 1 Research and development 965.5 770.7 661.5 1 Selling, general and administrative SG&A 2,114.0 1,751.4 1,526.3 Gain loss on sale of product rights 5 18.1 6.0 16.5 Reorganization costs 6 24.3 34.3 Integration and acquisition costs 4 25.2 13.7 8.0 Total operating expenses 3,732.0 3,154.2 2,677.0 Operating income 949.2 1,109.2 794.1 Interest income 3.1 1.9 2.4 Interest expense 38.2 39.1 35.1 Other expense income, net 25 2.7 18.1 7.9 Total other expense, net 37.8 19.1 24.8 Income before income taxes and equity in earnings of equity method investees 911.4 1,090.1 769.3 Income taxes 27 167.0 227.6 182.7 Equity in earnings of equity method investees, net of taxes 1.0 2.5 1.4 Net income 745.4 865.0 588.0 Earnings per Ordinary Share basic 134.2c 156.9c 107.7c Earnings per Ordinary Share diluted 130.9c 150.9c 105.3c Weighted average number of shares millions : Basic 23 555.4 551.1 546.2 Diluted 23 593.5 595.4 590.3 1 Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.7 million for the year to December 31, 2012 2011: $1.7 million, 2010: $1.7 million.
Research and development costs include intangible asset impairment charges of $71.2 million for the year to December 31, 2012 2011: $16.0 million, 2010: $nil.
SG&A costs includes amortization and impairment charges of intangible assets relating to intellectual property rights acquired of $320.8 million including impairment losses of $126.7 million for the year to December 31, 2012 2011: $165.0 million including impairment losses of $nil, 2010: $176.2 million including impairment losses of $42.7 million.
The accompanying notes are an integral part of these consolidated financial statements.
